The SYNTAX score on its way out or … towards artificial intelligence: Part II

Patrick W. Serruys; Ply Chichareon; Rodrigo Modolo; David M. Leaman; Johan H.C. Reiber; Håkan Emanuelsson; Carlo di Mario; Nico H.J. Pijls; Marie Angèle Morel; Marco Valgimigli; Vasim Farooq; David van Klaveren; Davide Capodanno; Daniele Andreini; Christos V. Bourantas; Justin Davies; Adrian P. Banning; Javier Escaned; Jan J. Piek; Mauro Echavarria-Pinto; Charles A. Taylor; Brian Thomsen; Carlos Collet; Giulio Pompilio; Antonio L. Bartorelli; Ben Glocker; Ovidiu Dressler; Gregg W. Stone; Yoshinobu Onuma

doi:10.4244/eij-d-19-00543b

The SYNTAX score on its way out or … towards artificial intelligence: Part II

Patrick W. Serruys
, Ply Chichareon
, Rodrigo Modolo
, David M. Leaman
, Johan H.C. Reiber
, Håkan Emanuelsson
, Carlo di Mario
, Nico H.J. Pijls
, Marie Angèle Morel
, Marco Valgimigli
, Vasim Farooq
, David van Klaveren
, Davide Capodanno
, Daniele Andreini
, Christos V. Bourantas
, Justin Davies
, Adrian P. Banning
, Javier Escaned
, Jan J. Piek
, Mauro Echavarria-Pinto

Charles A. Taylor, Brian Thomsen, Carlos Collet, Giulio Pompilio, Antonio L. Bartorelli, Ben Glocker, Ovidiu Dressler, Gregg W. Stone, Yoshinobu Onuma

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Original language	English
Pages (from-to)	60-75
Number of pages	16
Journal	EuroIntervention
Volume	16
Issue number	1
DOIs	https://doi.org/10.4244/eij-d-19-00543b
State	Published - 2021
Externally published	Yes

Access to Document

10.4244/eij-d-19-00543b

Cite this

Serruys, P. W., Chichareon, P., Modolo, R., Leaman, D. M., Reiber, J. H. C., Emanuelsson, H., di Mario, C., Pijls, N. H. J., Morel, M. A., Valgimigli, M., Farooq, V., van Klaveren, D., Capodanno, D., Andreini, D., Bourantas, C. V., Davies, J., Banning, A. P., Escaned, J., Piek, J. J., ... Onuma, Y. (2021). The SYNTAX score on its way out or … towards artificial intelligence: Part II. EuroIntervention, 16(1), 60-75. https://doi.org/10.4244/eij-d-19-00543b

@article{a9f2adff35ba4241b865d5e244aa99e1,

title = "The SYNTAX score on its way out or … towards artificial intelligence: Part II",

author = "Serruys, \{Patrick W.\} and Ply Chichareon and Rodrigo Modolo and Leaman, \{David M.\} and Reiber, \{Johan H.C.\} and H{\aa}kan Emanuelsson and \{di Mario\}, Carlo and Pijls, \{Nico H.J.\} and Morel, \{Marie Ang{\`e}le\} and Marco Valgimigli and Vasim Farooq and \{van Klaveren\}, David and Davide Capodanno and Daniele Andreini and Bourantas, \{Christos V.\} and Justin Davies and Banning, \{Adrian P.\} and Javier Escaned and Piek, \{Jan J.\} and Mauro Echavarria-Pinto and Taylor, \{Charles A.\} and Brian Thomsen and Carlos Collet and Giulio Pompilio and Bartorelli, \{Antonio L.\} and Ben Glocker and Ovidiu Dressler and Stone, \{Gregg W.\} and Yoshinobu Onuma",

note = "Funding Information: P.W. Serruys reports personal fees from Abbott Laboratories, AstraZeneca, Biotronik, Cardialysis, GLG Research, Medtronic, Sino Medical Sciences Technology, Soci{\'e}t{\'e} Europa Digital \& Publishing, Stentys France, Svelte Medical Systems, Philips/ Volcano, St. Jude Medical, Qualimed, and Xeltis, outside the submitted work. P. Chichareon reports a research grant from Biosensors outside the submitted work. R. Modolo has received research grants from Biosensors outside the submitted work and from the Sao Paulo Research Foundation (FAPESP – grant number 2017/22013-8). N. Pijls has received institutional research grants from Abbott, Hexacath and HeartFlow, is a consultant for Abbott, Opsens, and GE Healthcare, and possesses equity in Philips, HeartFlow, and ASML. M. Valgimigli reports grants and personal fees from Abbott, Terumo and AstraZeneca, personal fees from Chiesi, Bayer, Daiichi Sankyo, Amgen, Alvimedica, Idorsia, Biosensors, CoreFlow, Vifor and Bristol-Myers Squibb, and grants from Medicure, outside the submitted work. J. Davies reports grants, personal fees and other from Philips Volcano, outside the submitted work; in addition, J. Davies has a patent iFR with royalties paid by Philips Volcano to Imperial College London. A. Banning is partially supported by the NIHR Oxford Biomedical Research Centre and reports grants from Boston Scientific and personal fees from Boston Scientific, Medtronic and Abbott Vascular, during the conduct of the study. J.J. Piek reports non-financial support from Abbott Vascular and personal fees and non-financial support from Philips/Volcano, outside the submitted work. B. Thomsen is an employee of GE Healthcare. B. Glocker reports grants from HeartFlow, and the European Commission, during the conduct of the study, personal fees from Kheiron Medical Technologies, Definiens, Axon Advisors, and GlaxoSmithKline, grants from UKRI, EPSRC, Innovate UK, and MRC/NIHR, outside the submitted work. C. Collet reports grants and personal fees from HeartFlow Inc, and personal fees from Philips and Abbott Vascular, outside the submitted work. G.W. Stone reports personal fees from Terumo, Amaranth, Shockwave, Valfix, TherOx, Reva, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Matrizyme, Miracor, Neovasc, V-wave, Abiomed, Claret, Backbeat, Sirtex and MAIA Pharmaceuticals, personal fees and other from Ancora, Qool Therapeutics and SpectraWave, other from Cagent, Applied Therapeutics, Biostar family of funds, and MedFocus family of funds, outside the submitted work; Columbia University, his employer, receives royalties from Abbott for sales of the MitraClip. Y. Onuma reports being a member of the advisory board of Abbott Vascular. C. Taylor reports being a shareholder in and an employee of HeartFlow. The other authors have no conflicts of interest to declare. The Guest Editor is a consultant for Edwards Lifesciences.",

year = "2021",

doi = "10.4244/eij-d-19-00543b",

language = "English",

volume = "16",

pages = "60--75",

journal = "EuroIntervention",

issn = "1774-024X",

publisher = "Europa Group",

number = "1",

}

Serruys, PW, Chichareon, P, Modolo, R, Leaman, DM, Reiber, JHC, Emanuelsson, H, di Mario, C, Pijls, NHJ, Morel, MA, Valgimigli, M, Farooq, V, van Klaveren, D, Capodanno, D, Andreini, D, Bourantas, CV, Davies, J, Banning, AP, Escaned, J, Piek, JJ, Echavarria-Pinto, M, Taylor, CA, Thomsen, B, Collet, C, Pompilio, G, Bartorelli, AL, Glocker, B, Dressler, O, Stone, GW & Onuma, Y 2021, 'The SYNTAX score on its way out or … towards artificial intelligence: Part II', EuroIntervention, vol. 16, no. 1, pp. 60-75. https://doi.org/10.4244/eij-d-19-00543b

TY - JOUR

T1 - The SYNTAX score on its way out or … towards artificial intelligence

T2 - Part II

AU - Serruys, Patrick W.

AU - Chichareon, Ply

AU - Modolo, Rodrigo

AU - Leaman, David M.

AU - Reiber, Johan H.C.

AU - Emanuelsson, Håkan

AU - di Mario, Carlo

AU - Pijls, Nico H.J.

AU - Morel, Marie Angèle

AU - Valgimigli, Marco

AU - Farooq, Vasim

AU - van Klaveren, David

AU - Capodanno, Davide

AU - Andreini, Daniele

AU - Bourantas, Christos V.

AU - Davies, Justin

AU - Banning, Adrian P.

AU - Escaned, Javier

AU - Piek, Jan J.

AU - Echavarria-Pinto, Mauro

AU - Taylor, Charles A.

AU - Thomsen, Brian

AU - Collet, Carlos

AU - Pompilio, Giulio

AU - Bartorelli, Antonio L.

AU - Glocker, Ben

AU - Dressler, Ovidiu

AU - Stone, Gregg W.

AU - Onuma, Yoshinobu

N1 - Funding Information: P.W. Serruys reports personal fees from Abbott Laboratories, AstraZeneca, Biotronik, Cardialysis, GLG Research, Medtronic, Sino Medical Sciences Technology, Société Europa Digital & Publishing, Stentys France, Svelte Medical Systems, Philips/ Volcano, St. Jude Medical, Qualimed, and Xeltis, outside the submitted work. P. Chichareon reports a research grant from Biosensors outside the submitted work. R. Modolo has received research grants from Biosensors outside the submitted work and from the Sao Paulo Research Foundation (FAPESP – grant number 2017/22013-8). N. Pijls has received institutional research grants from Abbott, Hexacath and HeartFlow, is a consultant for Abbott, Opsens, and GE Healthcare, and possesses equity in Philips, HeartFlow, and ASML. M. Valgimigli reports grants and personal fees from Abbott, Terumo and AstraZeneca, personal fees from Chiesi, Bayer, Daiichi Sankyo, Amgen, Alvimedica, Idorsia, Biosensors, CoreFlow, Vifor and Bristol-Myers Squibb, and grants from Medicure, outside the submitted work. J. Davies reports grants, personal fees and other from Philips Volcano, outside the submitted work; in addition, J. Davies has a patent iFR with royalties paid by Philips Volcano to Imperial College London. A. Banning is partially supported by the NIHR Oxford Biomedical Research Centre and reports grants from Boston Scientific and personal fees from Boston Scientific, Medtronic and Abbott Vascular, during the conduct of the study. J.J. Piek reports non-financial support from Abbott Vascular and personal fees and non-financial support from Philips/Volcano, outside the submitted work. B. Thomsen is an employee of GE Healthcare. B. Glocker reports grants from HeartFlow, and the European Commission, during the conduct of the study, personal fees from Kheiron Medical Technologies, Definiens, Axon Advisors, and GlaxoSmithKline, grants from UKRI, EPSRC, Innovate UK, and MRC/NIHR, outside the submitted work. C. Collet reports grants and personal fees from HeartFlow Inc, and personal fees from Philips and Abbott Vascular, outside the submitted work. G.W. Stone reports personal fees from Terumo, Amaranth, Shockwave, Valfix, TherOx, Reva, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Matrizyme, Miracor, Neovasc, V-wave, Abiomed, Claret, Backbeat, Sirtex and MAIA Pharmaceuticals, personal fees and other from Ancora, Qool Therapeutics and SpectraWave, other from Cagent, Applied Therapeutics, Biostar family of funds, and MedFocus family of funds, outside the submitted work; Columbia University, his employer, receives royalties from Abbott for sales of the MitraClip. Y. Onuma reports being a member of the advisory board of Abbott Vascular. C. Taylor reports being a shareholder in and an employee of HeartFlow. The other authors have no conflicts of interest to declare. The Guest Editor is a consultant for Edwards Lifesciences.

PY - 2021

Y1 - 2021

UR - https://www.scopus.com/pages/publications/85085156947

U2 - 10.4244/eij-d-19-00543b

DO - 10.4244/eij-d-19-00543b

M3 - Article

C2 - 31651398

AN - SCOPUS:85085156947

SN - 1774-024X

VL - 16

SP - 60

EP - 75

JO - EuroIntervention

JF - EuroIntervention

IS - 1

ER -